OVT for Epicondylosis (Tennis Elbow)
A Prospective, Open-Label, Multi-Center Post-Market Clinical Follow-Up Study to Evaluate the Residual Risk of OrthoVisc®-T (OVT) in the Treatment of Chronic Lateral Epicondylosis (Tennis Elbow)
Sponsor: Anika Therapeutics, Inc.
Listed as NCT04026191, this NA trial focuses on Epicondylitis, Lateral and Tendinopathy, Elbow and remains completed. Sponsored by Anika Therapeutics, Inc., it has been updated 7 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2022 — Jul 2024 [monthly]
Completed NA
-
Feb 2021 — Jan 2022 [monthly]
Completed NA
Status: Recruiting → Completed
▶ Show 2 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Recruiting NA
-
Aug 2019 — Jan 2021 [monthly]
Recruiting NA
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anika Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .